GGHC
RGNX icon

Gilder Gagnon Howe & Co’s Regenxbio RGNX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-14,466
Closed -$240K – 256
2015
Q4 		$240K Sell
14,466
-5,529
-28% -$110K ﹤0.01% 209
2015
Q3 		$440K Buy
+19,995
New +$510K 0.01% 208

Other funds holding RGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Gilder Gagnon Howe & Co's RGNX Position: Q1 2016 in Review

Gilder Gagnon Howe & Co sold out of Regenxbio (RGNX) in Q1 2016, closing a stake of 14,466 shares — an estimated $240K sold.

Gilder Gagnon Howe & Co first reported a position in RGNX in Q3 2015 and held it in 2 quarters. The position peaked at $440K in Q3 2015. 64 funds tracked by Wall St. Rank hold RGNX as of Q1 2016.

  • Gilder Gagnon Howe & Co reported no remaining Regenxbio position as of Q1 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 14,466 Regenxbio shares in Q1 2016, an estimated $240K.
  • Gilder Gagnon Howe & Co first reported a position in Regenxbio in Q3 2015 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Regenxbio position peaked at $440K in Q3 2015.
  • 64 funds tracked by Wall St. Rank held Regenxbio as of Q1 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2016, filed 3 May 2016.